Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults
- PMID: 28542097
- PMCID: PMC5502740
- DOI: 10.1097/FPC.0000000000000284
Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults
Abstract
Background: Anthracyclines are important chemotherapeutic agents, but their use is limited by cardiotoxicity. Candidate gene and genome-wide studies have identified putative risk loci for overt cardiotoxicity and heart failure, but there has been no comprehensive assessment of genomic variation influencing the intermediate phenotype of anthracycline-related changes in left ventricular (LV) function. The purpose of this study was to identify genetic factors influencing changes in LV function after anthracycline chemotherapy.
Methods: We conducted a genome-wide association study (GWAS) of change in LV function after anthracycline exposure in 385 patients identified from BioVU, a resource linking DNA samples to de-identified electronic medical record data. Variants with P values less than 1×10 were independently tested for replication in a cohort of 181 anthracycline-exposed patients from a prospective clinical trial. Pathway analysis was performed to assess combined effects of multiple genetic variants.
Results: Both cohorts were middle-aged adults of predominantly European descent. Among 11 candidate loci identified in discovery GWAS, one single nucleotide polymorphism near PR domain containing 2, with ZNF domain (PRDM2), rs7542939, had a combined P value of 6.5×10 in meta-analysis. Eighteen Kyoto Encyclopedia of Gene and Genomes pathways showed strong enrichment for variants associated with the primary outcome. Identified pathways related to DNA repair, cellular metabolism, and cardiac remodeling.
Conclusion: Using genome-wide association we identified a novel candidate susceptibility locus near PRDM2. Variation in genes belonging to pathways related to DNA repair, metabolism, and cardiac remodeling may influence changes in LV function after anthracycline exposure.
Conflict of interest statement
Conflicts of interest: None declared.
Figures


References
-
- Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. PEDIATRICS. 2008;121:e387–96. - PubMed
-
- Forrest GL, Gonzalez B, Tseng W, Li X, Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res. 2000;60:5158–5164. - PubMed
-
- Dell’Acqua G, Polishchuck R, Fallon JT, Gordon JW. Cardiac resistance to adriamycin in transgenic mice expressing a rat alpha-cardiac myosin heavy chain/human multiple drug resistance 1 fusion gene. Hum Gene Ther. 1999;10:1269–1279. - PubMed
-
- Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Medicine. 2012;18:1639–1642. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1 TR000445/TR/NCATS NIH HHS/United States
- K08 HL121174/HL/NHLBI NIH HHS/United States
- T32 GM007569/GM/NIGMS NIH HHS/United States
- R01 HL140074/HL/NHLBI NIH HHS/United States
- L30 HL121054/HL/NHLBI NIH HHS/United States
- F30 HL127962/HL/NHLBI NIH HHS/United States
- U01 HG008672/HG/NHGRI NIH HHS/United States
- T32 HL105334/HL/NHLBI NIH HHS/United States
- 16FTF30130005/AHA/American Heart Association-American Stroke Association/United States
- T32 GM007347/GM/NIGMS NIH HHS/United States
- KL2 TR000446/TR/NCATS NIH HHS/United States
- RC2 GM092618/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials